News

Filter

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Alzheimer’s drug market to triple to $14.3 billion by 2020, says DR

09-10-2011

The Alzheimer’s disease drug market will nearly triple over the next 10 years, increasing from $5.4…

bapineuzumabEli LillyGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalsolanezumab

Alzheimer's drug market to more than triple to $13.3 billion in 2019 in top seven markets, fuelled by new biologic agents

10-09-2010

The emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease…

bapineuzumabBiotechnologydonepezilEli LillyJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalsolanezumab

Back to top